• Caleb E Kroll, Brandon Schartz, Marlis Gonzalez-Fernandez, Andrew H Gordon, Mosunmola Babade, Michael A Erdek, Nagy Mekhail, and Steven P Cohen.
• Departments of *Anesthesiology & Critical Care Medicine †Physical Medicine & Rehabilitation, Johns Hopkins School of Medicine, Baltimore §Department of Anesthesiology, Walter Reed National Military Medical Center, Bethesda, MD ‡Department of Pain Medicine, Cleveland Clinic Foundation, Cleveland, OH.
• Clin J Pain. 2014 Jan 1; 30 (1): 55-62.

ObjectiveSuperior hypogastric plexus neurolysis (SHP-N) has been shown in uncontrolled studies to provide intermediate-term benefit in a majority of patients with pain secondary to genitourinary, gynecologic, and colorectal cancers. The purpose of this is to determine factors associated with treatment outcome.Materials And MethodsPatients who underwent SHP-N after a positive prognostic block were identified based on diagnostic classification and procedural codes from databases at 2 large teaching hospitals. A host of demographic, clinical, and treatment factors were examined for their association with treatment success, which was defined as ≥50% pain relief lasting ≥1 month.ResultsA total of 53.1% of 32 patients with sufficient medical records for analysis experienced a positive outcome. Those with a positive outcome were older (mean age 59.6 y, SD 13.1 vs. 47.8, SD 15.6; P=0.03), less likely to have pelvic pain (36.8% success rate, P=0.04), and more likely to have bladder cancer (88.9% success rate; P=0.01) than those with a negative outcome. In stratified analysis, female were more likely to have positive outcome if they did not have pelvic pain compared to those that did (P=0.008). This difference was not significant for males.DiscussionSelecting patients based on demographic and clinical variables may improve treatment outcomes for SHP-N. Larger, prospective studies are needed to confirm our results and better refine selection criteria better.

24 keywords...

hide…